Core Viewpoint - Elysium Biotech (01061) shares rose over 10%, currently up 9.39% at HKD 5.94, with a trading volume of HKD 9.3261 million following the announcement of a joint development licensing agreement with Shanghai Junshi Biosciences Co., Ltd. [1] Group 1 - The joint development licensing agreement involves Elysium's wholly-owned subsidiaries and Junshi Biosciences for the co-development of licensed products [1] - The licensed product is a recombinant anti-VEGF humanized monoclonal antibody intended for the treatment of wet age-related macular degeneration (wet AMD) [1] - The biological product application for HLX04-O, an anti-VEGF ocular injection, has recently been accepted by the National Medical Products Administration (NMPA) of China [1] Group 2 - HLX04-O is developed based on Junshi's independently developed Hanbeitai (Bevacizumab injection), optimized for ophthalmic use while maintaining the active ingredient [1] - The new ophthalmic formulation is aimed at treating wet AMD, with adjustments made to the prescription, specifications, and production process [1]

Group 1 - The core point of the article is that Edding Biotechnology (01061.HK) has received acceptance for its biopharmaceutical license application for the anti-VEGF eye injection product HLX04-O, intended for the treatment of wet AMD, from the National Medical Products Administration (NMPA) in China [1] - HLX04-O is developed based on the independently researched Hanbeitai (Bevacizumab injection) by the company, optimized for ophthalmic use in terms of formulation, specifications, and production processes while maintaining the same active ingredient [1] - As of the announcement date, there are no approved Bevacizumab products for the treatment of wet AMD in China, with projected sales for drugs targeting wet AMD in China estimated at approximately RMB 4.9 billion for 2024 according to the latest data from IQVIA CHPA [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 茲提述(i)億勝生物科技有限公司（「本公司」）日期為二零二零年十月十五日之公佈（「該公 佈」），內容有關受許人（均為本公司之全資附屬公司）與上海復宏漢霖生物技術股份有限公司 （「復宏漢霖」）訂立共同開發許可協議，以根據共同開發許可協議之條款共同開發許可產品及 向受許人授出有關許可產品之獨家權利；及(ii)本公司於二零二一年一月至二零二五年四月期 間刊發之若干公佈，內容有關上述事項的若干最新情況。許可產品為內含重組抗血管內皮生 長因子人源化單克隆抗體（「anti-VEGF」）作為原料藥之生物藥品，擬用於治療滲出性（濕性） 老年性黃斑部病變（「濕性AMD」）。除另有指明者外，本公佈所用詞彙與該公佈所界定者具有 相同涵義。 有關開發HLX04-O之進一步最新情況 （於開曼群島註冊成立之有限公司） （股份代號：1061） 有關滲出性（濕性）老年性黃斑部病變之治療 許可產品 生物製品許可申請已受理 現時市況 截至本 ...

Core Viewpoint - Fosun Pharma has returned to double-digit profit growth in 2024 after a decline in 2023, with a net profit of 2.77 billion yuan, a year-on-year increase of 16.08% despite a slight revenue drop of 0.8% to 41.068 billion yuan [1][2]. Group 1: Financial Performance - In 2024, Fosun Pharma's revenue was 41.068 billion yuan, down 0.8% year-on-year, while net profit reached 2.77 billion yuan, up 16.08% [1]. - The oncology and immunomodulation segment generated 8.085 billion yuan in revenue, a year-on-year increase of 5.84%, driven by sales growth of several key innovative drugs [2]. - Subsidiary Fuhong Hanlin achieved approximately 5.724 billion yuan in revenue, a 6.1% increase, and a net profit of about 821 million yuan, marking a 50.3% growth [2][3]. Group 2: Strategic Focus and Asset Management - Fosun Pharma is focusing on the development of innovative drugs and high-value medical devices, leading to a transformation in product structure and strategy [1]. - The company is actively divesting non-core assets, having raised nearly 3 billion yuan in cash since the beginning of 2024, and aims to optimize asset structure and enhance asset efficiency [6]. - The company plans to continue shedding non-strategic and low-efficiency assets to concentrate resources on core business areas, with a goal of maintaining a healthy cash flow [6]. Group 3: Impact of Biosimilar Drug Procurement - The potential nationwide procurement of biosimilar drugs is expected to impact the market, with the first round likely to occur within the year, although specific products and rules remain uncertain [4]. - The development of biosimilar drugs has significantly improved drug accessibility and contributed to cost savings in healthcare, despite the high R&D costs associated with these products [4][5]. - Fosun Pharma's chairman expressed the need for a balance between expanding drug accessibility through procurement and allowing space for the biosimilar industry to grow [4].